ISSN: 1699-048X
Journal Home
Journal Guideline
Clinical and Translational Oncology Q2 Unclaimed
Clinical and Translational Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 65. It has a price of 3290 €. It has an SJR impact factor of 0,903 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,903.
Clinical and Translational Oncology focuses its scope in these topics and keywords: patients, cancer, guideline, nutritional, management, melanoma, clinical, bevacizumab, braf, treatment, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
3290 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
0,903
SJR Impact factor65
H Index483
Total Docs (Last Year)788
Total Docs (3 years)22402
Total Refs2363
Total Cites (3 years)771
Citable Docs (3 years)2.96
Cites/Doc (2 years)46.38
Ref/DocOther journals with similar parameters
Neuro-Oncology Practice Q2
Revista de Saude Publica Q2
Human Vaccines and Immunotherapeutics Q2
British Journal of Nutrition Q2
Neurodegenerative disease management Q2
Compare this journals
Aims and Scope
Best articles by citations
Effects of zoledronate on the radiation-induced collagen breakdown: a prospective randomized clinical trial
View moreDifferential expression of S1P receptor subtypes in human bladder transitional cell carcinoma
View moreInvolvement of RalB in the effect of geranylgeranyltransferase I on glioma cell migration and invasion
View moreAnlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma
View moreDosimetry study of 18F-FMISO+PET/CT hypoxia imaging guidance on intensity-modulated radiation therapy for non-small cell lung cancer
View moreSmoking habits in elderly lung cancer patients: still no changes in epidemiology? A single-center experience
View moreSolitary metastasis in a nasal fossa as the first manifestation of a renal carcinoma
View moreQuality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial
View moreMethylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction
View moreSynovial sarcoma in children. A single centre experience
View moreMolecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications
View moreCorrection to: SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
View moreSuperoxidase dismutase (SOD) topical use in oncologic patients: treatment of acute cutaneous toxicity secondary to radiotherapy
View moreSubtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial
View moreManagement of high-risk and advanced basal cell carcinoma
View moreVEGFR2 inhibition by RNA interference affects cell proliferation, migration, invasion, and response to radiation in Calu-1 cells
View moreFESEO and Clinical & Translational Oncology: a brief historical perspective
View moreSacred herbs
View moreIdentification of the Rock-dependent transcriptome in rodent fibroblasts
View moreGemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer
View moreA new mutation in the hMSH2 gene in a Spanish Lynch syndrome family
View moreActive study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)
View moreConsensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma
View moreEffect of exosome biomarkers for diagnosis and prognosis of breast cancer patients
View more
Comments